Halozyme Therapeutics, Inc. (HALO) Financials

HALO Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 1.7 billion 1.6 billion
2023-09-30 1.9 billion 1.6 billion
2023-06-30 1.8 billion 1.7 billion
2023-03-31 1.7 billion 1.6 billion

HALO Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 99.8 million 9.7 million
2023-09-30 129.5 million 9.4 million
2023-06-30 68.5 million 9.6 million
2023-03-31 75.6 million 8.0 million

HALO Net Income

Graph available only for supporters. Become a supporter to see it.
DateNet Income
2023-12-31 85.4 million
2023-09-30 81.8 million
2023-06-30 74.8 million
2023-03-31 39.6 million

HALO Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 336.0 million - -
2023-09-30 483.3 million - -
2023-06-30 348.3 million - -
2023-03-31 275.6 million - -

HALO Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 134.2 million
2023-09-30 134.1 million
2023-06-30 133.5 million
2023-03-31 137.9 million

HALO Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 2.6 million 21.3 million 37.6 million -
2023-09-30 2.9 million 17.3 million 35.3 million -
2023-06-30 1.6 million 19.7 million 38.9 million -
2023-03-31 11.4 million 18.0 million 37.4 million -

HALO Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 230.0 million 52.3 million
2023-09-30 216.0 million 54.8 million
2023-06-30 221.0 million 50.1 million
2023-03-31 162.1 million 35.2 million

HALO

Price: $39.30

52 week price:
29.85
45.00

Earnings Per Share: 2.10 USD

P/E Ratio: 18.88

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 402302

Ebitda: 127.5 million

Market Capitalization: 5.1 billion

Links: